Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaKMDA -0.73%86 3-Year EBITDA Growth Rate is 41.50% as of Jun. 2026, which is 77% above its 10-year median of 23.40. GuruFocus rates KMDA with a GF Score™ of 86/100 and a GF Value™ of $8.60 (Fairly Valued). The stock has 1 warning sign investors should review. Among 804 Drug Manufacturers companies, Kamada ranks better than 85.82% on this metric.
During the past 12 months, Kamada's average EBITDA Per Share Growth Rate was 23.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kamada was 75.30% per year. The lowest was -47.00% per year. And the median was 23.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kamada 3-Year EBITDA Growth Rate Related Terms
KMDA vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Kamada's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 41.50% mean?
Kamada (KMDA) has a 3-Year EBITDA Growth Rate of 41.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kamada and its competitors. This is 77% above median its historical median of 23.40. According to the industry distribution chart, Kamada ranks #114 out of 804 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Kamada's 3-Year EBITDA Growth Rate too high?
Kamada's current 3-Year EBITDA Growth Rate of 41.50% is 77% above median its 10-year median of 23.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Kamada's value of 41.50% is 366.3% above this industry median. Based on the distribution chart, Kamada ranks #114 out of 804 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kamada has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kamada's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #114 out of 804 companies for 3-Year EBITDA Growth Rate. This places Kamada in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Kamada's value of 41.50% is 366.3% above this benchmark. While the company's 10-year median is 23.40 vs. the industry median of 8.90, Kamada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current 3-Year EBITDA Growth Rate of 41.50% is 366.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kamada and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current 3-Year EBITDA Growth Rate is 41.50%, which is 77% above median its own 10-year median of 23.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (KMDA) is currently considered Fairly Valued. The stock's GF Value™ is $8.60, compared to a current price of $8.21 — trading 4.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 41.50%, which is 77% above median its 10-year median of 23.40 and 366.3% above the Drug Manufacturers industry median of 8.90. Kamada's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kamada (KMDA), the current 3-Year EBITDA Growth Rate is 41.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of $8.21 is trading 4.5% below its estimated GF Value™ of $8.60.
GuruFocus considers Kamada to be Fairly Valued.
Key valuation signals for KMDA:
3-Year EBITDA Growth Rate: 41.50% (77% above median its 10-year median of 23.40)
GF Value™: $8.60 vs. price of $8.21 (4.5% below fair value)
Industry Position: 366.3% above the Drug Manufacturers median (#114 of 804)
No single metric tells the full story. See the KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
86GF Score
Get the complete analysis for KMDA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMDA has been successfully added to your 
